Labetalol 75mg/5ml oral solution
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Labetalol
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Labetalol
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
WHO defined daily dose (DDD)
600 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 15 · Randomised trials: 28 · 1982–2026
Showing the 50 most relevant studies, sorted by most relevant.
Thomas R. Easterling, Shuchita Mundle, Hillary Bracken, et al.
The Lancet, 2019
- Antihypertensive Agents
- Blood Pressure
- India
Shashank Shekhar, N. Gupta, R. Kirubakaran, et al.
BJOG: An International Journal of Obstetrics & Gynaecology, 2016
- Antihypertensive Agents
- Cost-Benefit Analysis
- Labetalol
Lin Li, Wenxia Xie, Hao Xu, et al.
The Journal of Maternal-Fetal & Neonatal Medicine, 2023
Stephen T. Vermillion, James A. Scardo, Roger B. Newman, et al.
American Journal of Obstetrics and Gynecology, 1999
- Adrenergic beta-Antagonists
- Blood Pressure
- Calcium Channel Blockers
Hup RJ, Damen JAA, Terstappen J, et al.
2025
- Hypertension, Pregnancy-Induced
- Labetalol
- Methyldopa
ObjectiveConsidering safety and effectiveness of oral antihypertensive agents when treating hypertensive disorders of pregnancy, no preference can be stated between the 3 agents currently available. Therefore, this systematic review and network meta-analysis aims to determine the effects of antenatal treatment with methyldopa, labetalol, or nifedipine for hypertensive disorders of pregnancy regarding maternal or fetal/neonatal morbidity and mortality.Data sourcesOn August 25, 2023, an electronic search in PubMed/Medline, Embase, and CENTRAL was performed.Study eligibility criteriaRandomized controlled trials reporting on perinatal outcomes in hypertensive pregnancies treated with oral antihypertensive agents of interest (methyldopa, labetalol, or nifedipine) or placebo/no treatment were identified.Study appraisal and synthesis methodsQuality assessment was performed using the Cochrane Risk of Bias tool for randomized controlled trials and trustworthiness was assessed with the Trustworthiness in RAndomised Controlled Trials Checklist. Data on our predefined outcomes were extracted and relative risks were calculated in network estimates if possible.ResultsTwenty three trials (3989 women) were included in our network meta-analysis with an overall low-to-moderate quality. Compared to placebo/no treatment, labetalol and methyldopa significantly reduced the incidence of severe hypertension (including 8 studies, relative risk 0.20 [95% confidence interval 0.09-0.48] and 0.44 [0.20-0.99], respectively). In the network meta-analysis, labetalol vs nifedipine was associated with a reduction in preeclampsia (relative risk, 0.50 [0.28-0.87]; 15 studies) and preterm birth (relative risk, 0.68 [0.52-0.90]; 14 studies). No significant differences could be detected for any of the other outcomes of interest.ConclusionWhen comparing the oral antihypertensive agents currently available head-to-head, no significant differences in the primary outcome, severe hypertension, could be detected as well as on most of the secondary outcomes of interest. Considering the preference of labetalol over nifedipine regarding the outcomes preeclampsia and preterm birth, a modest favor for labetalol could be stated. Included studies however were of low overall quality warranting caution when interpreting results.
Abstract licence: CC BY
Hendriksen ED, Rieder M, Urbantke E
2026
- Labetalol
- Antihypertensive Agents
- Chemical and Drug Induced Liver Injury
Maciej Makarewicz, Jarosław D. Kasprzak, Jan Z. Peruga
Arterial Hypertension, 2023
Kanninen T, Ortiz V, Alvarez-Perez J, et al.
2025
- Hypertension, Pregnancy-Induced
- Labetalol
- Nifedipine
Wang CY, Bastian IN, Turrentine MA
2025
W. Frank Peacock, Daniel E. Hilleman, Phillip D. Levy, et al.
The American Journal of Emergency Medicine, 2011
- Acute Disease
- Antihypertensive Agents
- Hypertension
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
18 found
Half-life
1.7-6.1 hours
Mechanism
Labetalol non-selectively antagonizes beta-adrenergic receptors, and selectively…
Food interactions
1 warning
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
100mg
[A181853]…
Half-life
1.7-6.1 hours
[A181853]
Protein binding
50%
[A181853][L7727][L7730]
Volume of distribution
805L
[A181853]…
Metabolism
[A181835]…
Elimination
55-60%
[A181853]
Clearance
1500mL/min
[A181853]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Labetalol was granted FDA approval on 1 August 1984.[L7724]
[L7727]
Labetalol tablets are indicated alone or in combination with antihypertensives like thiazides and loop diuretics to manage hypertension.
[L7730]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1865 interactions
[L7727][L7730]
The intravenous LD50 in mice and rats is 50-60mg/kg.
[L7727][L7730]
Patients experiencing an overdose may present with excessive hypotension and bradycardia.
[L7727][L7730]
Patients should be placed on their back with their legs raised to maintain perfusion of the brain.
[L7727][L7730]
Oral overdoses may be treated with gastric lavage or emesis, bradycardia may be treated with atropine or epinephrine, cardiac failure may be treated with digitalis and a diuretic, hypotension may be treated with vasopressors, bronchospasms may be treated with epinephrine or a beta2 agonist, and seizures may be treated with diazepam.
[L7727][L7730]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A181853]
Bioavailability may be as low as 11% or as high as 86% and may increase in older patients or when taken with food.
[A181853]
[A181853]
[A181853][L7727][L7730]
[A181853]
In hypertensive patients, the volume of distribution is between 188-747L with an average of 392L.
[A181853]
[A181835]
This metabolite may be further metabolized to benzylacetone and 3-amino-(4-hydroxyphenyl)butane.
[A181835]
Labetalol in humans is mainly metabolized to glucuronide metabolites such as the O-phenyl-glucuronide and the N-glucuronide.
[A181853][L7727][L7730]
[A181853]
[A181853]
Proteins and enzymes this drug interacts with in the body
Involved in the regulation of sleep/wake behaviors PMID:31473062
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:12960149 PMID:15205344 PMID:15899824 PMID:22306008
Specifically present in limbal stem cells, where it plays a key role in corneal development and repair (By similarity)
Proteins that carry this drug through the body
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).
Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).
Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017
Appears to function in modulating the activity of the immune system during the acute-phase reaction
ATC C07BG01
ATC C07CG01
ATC C07AG01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Labetalol
Additional database identifiers
Drugs Product Database (DPD)
1896
ChemSpider
3734
BindingDB
25758
HUGO Gene Nomenclature Committee (HGNC)
HGNC:285
GenAtlas
ADRB1
GeneCards
ADRB1
GenBank Gene Database
J03019
GenBank Protein Database
178200
Guide to Pharmacology
28
UniProt Accession
ADRB1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:286
GenAtlas
ADRB2
GeneCards
ADRB2
GenBank Gene Database
Y00106
GenBank Protein Database
29371
Guide to Pharmacology
29
UniProt Accession
ADRB2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:277
GenAtlas
ADRA1A
GeneCards
ADRA1A
GenBank Gene Database
D25235
GenBank Protein Database
433201
Guide to Pharmacology
22
UniProt Accession
ADA1A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:278
GenAtlas
ADRA1B
GeneCards
ADRA1B
GenBank Gene Database
M99589
Guide to Pharmacology
23
UniProt Accession
ADA1B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:280
GenAtlas
ADRA1D
GeneCards
ADRA1D
GenBank Gene Database
M76446
GenBank Protein Database
177807
Guide to Pharmacology
24
UniProt Accession
ADA1D_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2625
GenAtlas
CYP2D6
GeneCards
CYP2D6
GenBank Gene Database
M20403
GenBank Protein Database
181350
Guide to Pharmacology
1329
UniProt Accession
CP2D6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2621
GeneCards
CYP2C19
GenBank Gene Database
M61854
GenBank Protein Database
181344
Guide to Pharmacology
1328
UniProt Accession
CP2CJ_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12530
GeneCards
UGT1A1
GenBank Gene Database
M57899
GenBank Protein Database
184473
Guide to Pharmacology
2990
UniProt Accession
UD11_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12554
GeneCards
UGT2B7
GenBank Gene Database
J05428
GenBank Protein Database
340080
UniProt Accession
UD2B7_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12541
GeneCards
UGT1A9
GenBank Gene Database
S55985
GenBank Protein Database
7690346
UniProt Accession
UD19_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:399
GenAtlas
ALB
GeneCards
ALB
GenBank Gene Database
V00494
GenBank Protein Database
28590
UniProt Accession
ALBU_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8498
GenAtlas
ORM1
GeneCards
ORM1
GenBank Gene Database
X02544
GenBank Protein Database
757907
UniProt Accession
A1AG1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8499
GeneCards
ORM2
GenBank Gene Database
BC015964
GenBank Protein Database
16359000
UniProt Accession
A1AG2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:46
GenAtlas
ABCB5
GeneCards
ABCB5
GenBank Gene Database
AY090613
UniProt Accession
ABCB5_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q958087), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.